Healthcare

• Aroa Biosurgery reported FY26 revenue of NZ$104 million, above its NZ$92 million to NZ$100 million constant currency guidance.

• Sonic grew FY26 revenue 13% to A$10,867 million and underlying EBITDA 11% to A$1,933 million, meeting its earnings guidance.

• Nexsen decided not to lodge the current StrepSure configuration with the US FDA and will enhance the device first.

• Filed two provisional patent applications covering candidate biomarker combinations for early ovarian cancer detection, ahead of initial proof-of-concept screening data.

• Healius agreed to sell Agilex Biolabs to Novotech for A$160 million enterprise value, with completion expected in second half FY2027.

• Cochlear booked FY26 sales revenue of A$2,343.4 million, down 1% reported but up 2% in constant currency.

• Ansell grew FY26 sales 6.8 per cent to US$2,140.2 million, with adjusted EBIT rising to US$321.9 million.